

Georg Greiner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2834260/publications.pdf>

Version: 2024-02-01

40
papers

910
citations

516215

16
h-index

476904

29
g-index

41
all docs

41
docs citations

41
times ranked

1378
citing authors

#	ARTICLE	IF	CITATIONS
1	Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal. <i>HemaSphere</i> , 2021, 5, e646.	1.2	128
2	Hereditary α -tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis. <i>Blood</i> , 2021, 137, 238-247.	0.6	113
3	Delineation of target expression profiles in CD34 ⁺ /CD38 ⁺ and CD34 ⁺ /CD38 ⁺ stem and progenitor cells in AML and CML. <i>Blood Advances</i> , 2020, 4, 5118-5132.	2.5	62
4	Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph ⁺ CML. <i>Clinical Cancer Research</i> , 2016, 22, 2051-2061.	3.2	52
5	Digital PCR: A Sensitive and Precise Method for KIT D816V Quantification in Mastocytosis. <i>Clinical Chemistry</i> , 2018, 64, 547-555.	1.5	49
6	Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms. <i>Mediators of Inflammation</i> , 2015, 2015, 1-17.	1.4	40
7	Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study. <i>Lancet Haematology</i> , 2021, 8, e194-e204.	2.2	39
8	Chloroquine inhibits human CD4 ⁺ T-cell activation by AP-1 signaling modulation. <i>Scientific Reports</i> , 2017, 7, 42191.	1.6	36
9	Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia. <i>Haematologica</i> , 2017, 102, 1519-1529.	1.7	36
10	The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis. <i>Haematologica</i> , 2018, 103, 799-809.	1.7	30
11	TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors. <i>Cancer Research</i> , 2021, 81, 5089-5101.	0.4	25
12	CCL2 is a KIT D816V-dependent modulator of the bone marrow microenvironment in systemic mastocytosis. <i>Blood</i> , 2017, 129, 371-382.	0.6	24
13	Genetic Regulation of Tryptase Production and Clinical Impact: Hereditary Alpha Tryptasemia, Mastocytosis and Beyond. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2458.	1.8	23
14	The tryptophan metabolite picolinic acid suppresses proliferation and metabolic activity of CD4 ⁺ T cells and inhibits c-Myc activation. <i>Journal of Leukocyte Biology</i> , 2016, 99, 583-594.	1.5	22
15	Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis. <i>Haematologica</i> , 2020, 105, 366-374.	1.7	21
16	Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 411.	1.8	21
17	Thyroid and androgen receptor signaling are antagonized by Crystallin in prostate cancer. <i>International Journal of Cancer</i> , 2021, 148, 731-747.	2.3	17
18	Incorporating Tryptase Genotyping Into the Workup and Diagnosis of Mast Cell Diseases and Reactions. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1964-1973.	2.0	17

#	ARTICLE	IF	CITATIONS
19	Establishment of keratinocyte cell lines from human hair follicles. <i>Scientific Reports</i> , 2018, 8, 13434.	1.6	16
20	CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML. <i>EBioMedicine</i> , 2019, 50, 111-121.	2.7	14
21	<scp>BRD4</scp> degradation blocks expression of <scp>MYC</scp> and multiple forms of stem cell resistance in Ph⁺ chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, 1215-1225.	2.0	14
22	Clonal Hematopoiesis of Indeterminate Potential: A Multidisciplinary Challenge in Personalized Hematology. <i>Journal of Personalized Medicine</i> , 2020, 10, 94.	1.1	12
23	STAT5 is Expressed in CD34+/CD38âˆ’ Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative Neoplasms. <i>Cancers</i> , 2020, 12, 1021.	1.7	12
24	Fasting metabolism modulates the interleukin-12/interleukin-10 cytokine axis. <i>PLoS ONE</i> , 2017, 12, e0180900.	1.1	12
25	Expansion of <i><scp>BCR</scp>/<scp>ABL</scp>1</i>⁺ cells requires <scp>PAK</scp>2 but not <scp>PAK</scp>1. <i>British Journal of Haematology</i> , 2017, 179, 229-241.	1.2	11
26	Alum triggers infiltration of human neutrophils ex vivo and causes lysosomal destabilization and mitochondrial membrane potentialâ€dependent NETâ€formation. <i>FASEB Journal</i> , 2020, 34, 14024-14041.	0.2	11
27	Detection of SARS-CoV-2 by real-time PCR under challenging pre-analytical conditions reveals independence of swab media and cooling chain. <i>Scientific Reports</i> , 2021, 11, 13592.	1.6	9
28	Microarray-Based Detection of Allergen-Reactive IgE in Patients with Mastocytosis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2761-2768.e16.	2.0	8
29	Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia. <i>Leukemia</i> , 2021, 35, 3176-3187.	3.3	8
30	Development of a fully automated high throughput PCR for the detection of SARS-CoV-2: The need for speed. <i>Virulence</i> , 2020, 11, 964-967.	1.8	7
31	A Multidisciplinary Intervention in Childhood Obesity Acutely Improves Insulin Resistance and Inflammatory Markers Independent From Body Composition. <i>Frontiers in Pediatrics</i> , 2020, 8, 52.	0.9	7
32	Deciphering the Mechanisms of Osteoblast-Induced Resistance of Leukemic Stem Cell (LSC) in Ph+ CML: Role of PI3-Kinase, BRD4 and MYC and Development of Strategies to Overcome Osteoblast-Induced Resistance. <i>Blood</i> , 2021, 138, 1481-1481.	0.6	6
33	The <scp>JAK</scp>2 blocker <scp>TG</scp>101209 is a potent inhibitor of clonogenic progenitor cell growth in patients with chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2018, 181, 137-139.	1.2	3
34	Comparison of <i>BCR-ABL1</i> quantification in peripheral blood and bone marrow using an International Scale-standardized assay for assessment of deep molecular response in chronic myeloid leukemia. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 1214-1222.	1.4	1
35	Combined Targeting of STAT3 and STAT5: A Novel Approach to Overcome Drug Resistance in Ph+ Cml. <i>Blood</i> , 2016, 128, 4241-4241.	0.6	1
36	Secondary basophilic leukemia in Ph-negative myeloid neoplasms: A distinct subset with poor prognosis. <i>Neoplasia</i> , 2021, 23, 1183-1191.	2.3	1

#	ARTICLE	IF	CITATIONS
37	<i>TET2</i> and <i>DNMT3A</i> Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors. <i>Blood</i> , 2020, 136, 4-4.	0.6	1
38	CCL-2 Is a KIT D816V-Dependent Modulator of Bone Marrow Remodeling and Microenvironmental Alterations in Systemic Mastocytosis. <i>Blood</i> , 2015, 126, 1635-1635.	0.6	0
39	Phenotyping of Disease-Initiating CD34 ⁺ /CD38 ⁺ Stem Cells in BCR-ABL1 ⁺ MPN Reveals Expression of Multiple Cytokine Receptors and Resistance-Related Antigens. <i>Blood</i> , 2020, 136, 53-53.	0.6	0
40	CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in KIT D816V ⁺ Neoplastic Mast Cells. <i>Cancers</i> , 2022, 14, 3070.	1.7	0